Asia Pacific Hepatitis B Infection Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 4.03 Billion |
 Market Size (Forecast Year) |
USD 6.52 Billion |
 CAGR |
% |
| Major Markets Players |
>亚太地区乙肝感染市场，按类型（慢性和急性）、按治疗方法（疫苗、抗病毒药物、免疫调节药物和手术）划分 - 行业趋势和预测至 2031 年
亚太地区乙肝感染市场分析与洞察
Data Bridge Market Research分析，亚太地区乙肝感染市场规模预计将从2023年的40.3亿美元增至2031年的65.2亿美元，在2024年至2031年的预测期内，复合年增长率为6.2%。
|
报告指标 |
细节 |
|
预测期 |
2024 至 2031 年 |
|
基准年 |
2023 |
|
历史岁月 |
2022（可定制为 2016 – 2021） |
|
定量单位 |
收入（十亿美元） |
|
涵盖的领域 |
类型（慢性和急性）、治疗（疫苗、抗病毒药物、免疫调节药物和手术） |
|
覆盖国家 |
中国、印度、日本、韩国、新加坡、泰国、马来西亚、印度尼西亚、澳大利亚、越南、新西兰、台湾、菲律宾以及亚太地区其他地区 |
|
涵盖的市场参与者 |
吉利德科学公司（美国）、葛兰素史克公司（英国）、Dynavax Technologies（美国）、罗氏公司（瑞士）、百时美施贵宝公司（美国）、默克夏普和 Dohme Corp.（美国）、诺华公司（瑞士）、Arrowhead Pharmaceuticals Inc.（美国）、Arbutus Biopharma（加拿大）、Teva Pharmaceuticals, Inc.（以色列）、Zydus Pharmaceuticals（印度）、Aurobindo Pharma（印度）、Lupin Pharmaceuticals, Inc.（印度）。 |
市场定义
亚太地区乙肝感染市场是指专注于诊断、治疗、预防和管理乙肝病毒(HBV) 感染的医疗保健行业。该市场涵盖广泛的产品和服务，包括疫苗、抗病毒药物、诊断测试、免疫调节剂和旨在治疗急性和慢性乙肝的治疗方法。乙肝是由 HBV 引起的一种传染性极强的肝病，可导致严重的健康并发症，如肝硬化、肝功能衰竭和肝细胞癌。该市场包括制药公司、生物技术公司、诊断服务提供商、医疗机构和研究机构，致力于开发先进的治疗方案。亚太地区乙肝患病率不断上升，加上人们意识的提高和政府遏制其传播的举措，是市场增长的主要驱动力。此外，诊断工具和新型疗法（如核苷类似物和免疫调节剂）的技术进步正在扩大治疗领域。乙肝病毒感染率、医疗保健可及性和疫苗接种覆盖率的地区差异也会影响市场动态，发展中国家存在尚未开发的增长机会。
亚太乙型肝炎感染市场动态。
本节旨在了解市场驱动因素、机遇、限制因素和挑战。下文将详细讨论所有这些内容：
司机
乙肝感染率不断上升
乙肝感染率的不断上升，对有效的诊断工具、疫苗和抗病毒治疗的需求不断增长，成为乙肝感染市场的重要驱动力。由于乙肝是肝硬化和肝癌等肝病的主要原因，感染率的上升，特别是在医疗基础设施不足的地区，加剧了对预防、管理和治疗方案的需求。慢性乙肝感染的蔓延，特别是在意识和疫苗接种计划较不完善的中低收入国家，进一步扩大了免疫、抗病毒治疗和先进诊断技术的市场。此外，制药公司正在投资研发更新、更有效的抗病毒药物和疫苗，以应对病毒的不断演变。急性和慢性病例的增加，特别是在高危人群中，给医疗保健系统带来了压力，迫使它们投资于改进的诊断、疫苗和抗病毒疗法。
克制
- 副作用和耐药性
副作用和耐药性限制了现有疗法的有效性和长期使用，是乙肝感染市场的重要制约因素。许多用于治疗乙肝的抗病毒药物会引起疲劳、恶心、肝毒性和肾损伤等不良反应，从而导致患者依从性差和治疗中断。这不仅妨碍了治疗的成功，而且减少了对某些药物的总体需求。此外，乙肝病毒耐药株的发展带来了另一个重大挑战，因为它降低了当前抗病毒疗法的疗效，并需要不断开发新药。随着对现有治疗的抵抗力增加，它为医疗保健提供者有效管理感染创造了障碍，限制了市场的增长潜力。这些挑战导致人们不愿开出长期抗病毒疗法，减缓了某些药物的采用，从而限制了市场扩张
机会
乙肝新药上市数量和新药许可数量不断增加
乙肝市场正在经历显著增长，这主要得益于几个关键因素，包括新药发布数量的增加和新药许可的增加。药物批准数量的激增在一定程度上是对更有效的抗病毒疗法和疫苗的持续需求的回应，这些疗法和疫苗可以管理和可能根除乙肝。这一趋势从主要制药公司加大对研发的投资中可见一斑，这些公司专注于提供更高疗效、更少副作用和增强患者依从性的创新治疗方案。此外，药物输送系统的进步和联合疗法的发展也促进了市场的扩张。乙肝药物市场份额的增长也受到该病日益流行的支持，特别是在亚太地区和撒哈拉以南非洲等感染率较高的地区。随着新疗法的出现和市场竞争的加剧，预计财务增长将强劲，预测表明未来几年市场价值将大幅增加。这种增长的基础是医疗支出的增加、医疗保健服务的普及以及对乙肝管理重要性的认识的提高。随着新参与者进入该领域、现有公司进行创新以及世界各地的医疗保健系统优先考虑乙肝治疗，市场可能会继续扩大。
挑战
- 乙肝治疗费用高昂
乙肝治疗的高成本给市场带来了重大挑战。造成这一挑战的主要因素之一是开发抗病毒药物和免疫调节剂的复杂性，这些药物可以有效控制病毒而不会引起严重的副作用。这种复杂性需要大量的研究、临床试验和监管部门的批准，所有这些都推高了最终产品的价格。此外，慢性乙肝治疗的持续性意味着患者通常面临长期费用，这可能会非常昂贵，特别是在医疗补贴或保险覆盖有限的地区。
另一个挑战是乙肝仿制药的供应有限。许多更有效的治疗方法仍受专利保护，这使得制药公司能够维持高价。缺乏竞争进一步加重了患者、医疗保健系统和政府的财务负担。此外，新型治疗方法（例如旨在彻底根除病毒的治疗方法）的开发仍处于早期阶段，短期内没有显著降低治疗成本的前景。
- 2022 年 5 月，根据乙肝基金会发表的文章，估计有 3 亿乙肝患者，只有 10% 得到诊断，而确诊患者中只有 22% 接受抗病毒治疗。在非洲，情况更加严峻，只有 2% 的慢性乙肝患者得到诊断，只有 0.1% 接受治疗。治疗的一个重大障碍是费用
最新动态
- 2024 年 9 月，吉利德科学与 Genesis Therapeutics 宣布建立战略合作伙伴关系，利用 Genesis 的 GEMS AI 平台发现和开发新型小分子疗法。吉利德获得了此次合作中产品的独家开发和商业化权利
- 2024 年 7 月，吉利德科学公司 (Gilead Sciences, Inc.) 公布了研究数据，展示了 Biktarvy 对不同 HIV 人群（包括西班牙裔/拉丁裔个体和患有合并症的老年人）的长期疗效和安全性。研究还重点介绍了每日一次和每周一次的给药方案
- 2024 年 2 月，GSK 完成了对 Aiolos Bio 的收购，其中包括有前景的用于治疗严重哮喘的 AIO-001 单克隆抗体。GSK 支付了 10 亿美元的预付款和高达 4 亿美元的里程碑付款，扩大了其呼吸生物制剂产品组合
亚太乙肝感染市场范围
亚太地区乙肝感染市场根据类型和治疗分为两个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
类型
- 慢性的
- 急性
根据类型，市场分为慢性和急性。
治疗
- 疫苗
- 抗病毒药物
- 免疫调节药物
- 外科手术
根据治疗方法，市场分为疫苗、抗病毒药物、免疫调节药物和手术。
亚太乙肝感染市场区域分析/见解
根据乙肝感染类型和治疗方法，亚太地区乙肝感染市场可分为两个显著的部分。
本市场报告涵盖的国家包括中国、印度、日本、韩国、新加坡、泰国、马来西亚、印度尼西亚、澳大利亚、越南、新西兰、台湾、菲律宾和亚太地区其他地区。
由于新药上市和乙肝新药许可的不断增加，中国有望在市场上占据主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了亚太品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战以及销售渠道的影响。
竞争格局和亚太乙肝感染市场动态市场份额分析
亚太地区乙肝感染市场动态市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位以及产品类型生命线曲线。以上提供的数据点仅与公司对市场的关注有关。
该市场的一些主要市场参与者包括吉利德科学公司（美国）、葛兰素史克公司（英国）、Dynavax Technologies（美国）、F. Hoffmann-La Roche Ltd（瑞士）、百时美施贵宝公司（美国）、默克夏普和 Dohme Corp.（美国）、诺华公司（瑞士）、Arrowhead Pharmaceuticals Inc.（美国）、Arbutus Biopharma（加拿大）、Teva Pharmaceuticals, Inc.（以色列）、Zydus Pharmaceuticals（印度）、Aurobindo Pharma（印度）、Lupin Pharmaceuticals, Inc.（印度）。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC HEPATITIS B INFECTION MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 THERAPEUTICS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
5 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: REGULATIONS
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION
5.2 NORTH AMERICA REGULATORY SCENARIO
5.3 EUROPE REGULATORY SCENARIO
5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO
5.5 SOUTH AMERICA REGULATORY SCENARIO
6 PIPELINE ANALYSIS
7 EPIDEMILIOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS
8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B
8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS AND DRUG RESISTANCE
8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION
8.3 OPPORTUNITY
8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B
8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION
8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS
8.4 CHALLENGES
8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH
8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS
9 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE
9.1 OVERVIEW
9.2 CHRONIC
9.3 ACUTE
10 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 VACCINE
10.2.1 HOSPITAL PHARMACIES
10.2.2 DRUGS STORES AND RETAIL PHARMACIES
10.2.3 ONLINE PHARMACIES
10.3 ANTIVIRAL DRUGS
10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF)
10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF)
10.3.3 ENTECAVIR
10.3.4 OTHERS
10.4 IMMUNE MODULATOR DRUGS
10.4.1 PEGYLATED INTERFERON
10.4.2 INTERFERON ALPHA
10.5 SURGERY
11 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY REGION
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 INDIA
11.1.3 INDONESIA
11.1.4 JAPAN
11.1.5 VIETNAM
11.1.6 PHILIPPINES
11.1.7 THAILAND
11.1.8 SOUTH KOREA
11.1.9 AUSTRALIA
11.1.10 SINGAPORE
11.1.11 MALAYSIA
11.1.12 NEW ZEALAND
11.1.13 TAIWAN
11.1.14 REST OF ASIA-PACIFIC
12 ASIA-PACIFIC HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 GILEAD SCIENCES, INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 GLAXOSMITHKLINE PLC
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 DYNAVAX TECHNOLOGIES CORPORATION
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 F. HOFFMAN-LA ROCHE LTD.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 BRISTOL-MYERS SQUIBB COMPANY
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 ARROWHEAD PHARMACEUTICALS, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 ARBUTUS BIOPHARMA
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT UPDATES
14.8 AUROBINDO PHARMA
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT UPDATES
14.9 LUPIN PHARMACEUTICALS, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT UPDATES
14.1 MERCK & CO., INC.,
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 NOVARTIS AG
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 TEVA PHARMACEUTICAL INDUSTRIES
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 ZYDUS PHARMACEUTICALS, INC.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 REVENUE
14.13.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
TABLE 1 ASIA-PACIFIC CLINICAL TRIAL AND PIPELINE A-LYSIS AS PER THE COMPANY
TABLE 2 DISTRIBUTION OF PRODUCTS OR PROJECTS BY PHASE
TABLE 3 COUNTRY WISE EPIDEMIOLOGY FOR HEPATITIS B
TABLE 4 COST OF HEPATITIS B MEDICATIONS: BRAND VS. GENERIC PRICES
TABLE 5 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 6 ASIA-PACIFIC CHRONIC IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 ASIA-PACIFIC ACUTE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 9 ASIA-PACIFIC VACCINE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 ASIA-PACIFIC VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 11 ASIA-PACIFIC ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 ASIA-PACIFIC ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 13 ASIA-PACIFIC IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 ASIA-PACIFIC IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 15 ASIA-PACIFIC SURGERY IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 17 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 18 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 19 ASIA-PACIFIC ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 20 ASIA-PACIFIC IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 21 CHINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 22 CHINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 23 CHINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 24 CHINA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 25 CHINA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 26 CHINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 27 INDIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 INDIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 29 INDIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 30 INDIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 31 INDIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 32 INDONESIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 INDONESIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 34 INDONESIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 35 INDONESIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 36 INDONESIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 37 JAPAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 38 JAPAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 39 JAPAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 40 JAPAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 41 JAPAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 42 VIETNAM HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 43 VIETNAM HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 44 VIETNAM ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 45 VIETNAM IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 46 VIETNAM VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 47 PHILIPPINES HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 PHILIPPINES HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 49 PHILIPPINES ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 50 PHILIPPINES IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 51 PHILIPPINES VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 52 THAILAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 THAILAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 54 THAILAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 55 THAILAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 56 THAILAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 57 SOUTH KOREA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 SOUTH KOREA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 59 SOUTH KOREA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 60 SOUTH KOREA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 61 SOUTH KOREA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 62 AUSTRALIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 AUSTRALIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 64 AUSTRALIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 65 AUSTRALIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 66 AUSTRALIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 67 SINGAPORE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 SINGAPORE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 69 SINGAPORE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 70 SINGAPORE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 71 SINGAPORE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 72 MALAYSIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 73 MALAYSIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 74 MALAYSIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 75 MALAYSIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 76 MALAYSIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 77 NEW ZEALAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 78 NEW ZEALAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 79 NEW ZEALAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 80 NEW ZEALAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 81 NEW ZEALAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 82 TAIWAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 83 TAIWAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 84 TAIWAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 85 TAIWAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 86 TAIWAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 87 REST OF ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
图片列表
FIGURE 1 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: SEGMENTATION
FIGURE 11 TWO SEGMENTS COMPRISE THE ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 ASIA-PACIFIC HEPATITIS B INFECTION MARKET
FIGURE 15 CHRONIC SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC HEPATITIS B INFECTION MARKET IN 2024 & 2031
FIGURE 16 DROC ANALYSIS
FIGURE 17 BURDEN OF HBV INFECTION IN THE GENERAL POPULATION BY WHO REGION, 2019
FIGURE 18 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TYPE, 2023
FIGURE 19 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 20 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 21 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TREATMENT, 2023
FIGURE 23 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 24 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 25 ASIA-PACIFIC HEPATITIS B INFECTION MARKET BY TREATMENT, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, SNAPSHOT
FIGURE 27 ASIA-PACIFIC HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
